10-K: Amphastar Reports Mixed 2025 Results Amid Product Launches

Amphastar Pharmaceuticals, Inc. reported a slight revenue decline in 2025 to $719.9 million, down 2% from 2024, with net income decreasing to $98.1 million, while launching new products and expanding its pipeline.

Summary

• Net revenues for the year ended December 31, 2025, were $719.9 million, a 2% decrease from $732.0 million in 2024.
• Net income for 2025 was $98.1 million, down from $159.5 million in 2024 and $137.5 million in 2023.
• Gross profit decreased by 5% to $356.1 million in 2025, with gross margins falling from 51% in 2024 to 49% in 2025.
• Selling, distribution, and marketing expenses increased by 16% to $43.9 million in 2025, primarily due to expanded efforts for BAQSIMI and Primatene MIST.
• General and administrative expenses rose significantly by 51% to $85.9 million in 2025, largely due to a $23.1 million legal settlement.
• Research and development expenses increased by 16% to $85.8 million in 2025, including a $6.0 million upfront payment for a licensing agreement with Anji Biotechnology.
• BAQSIMI sales increased by 46% to $185.4 million in 2025, driven by increased unit volume as the company assumed full global distribution.
• Primatene MIST sales grew by 7% to $108.7 million in 2025 due to increased unit volumes and marketing efforts.
• Sales of epinephrine decreased by 25% to $70.6 million, impacted by lower unit volume and average selling price due to increased competition.
• Glucagon sales declined by 36% to $69.1 million, attributed to lower average selling prices and a market shift to ready-to-use products like BAQSIMI.
• Other products revenue increased by $4.0 million, primarily from new launches of albuterol sulfate inhalation aerosol and iron sucrose injection, partially offset by declines in enoxaparin and dextrose due to competition.
• The company launched iron sucrose injection in August 2025 and teriparatide injection in December 2025.
• The FDA approved Ipratropium Bromide HFA inhalation aerosol in February 2026, with a planned launch in early Q2 2026.
• Total debt increased to $610.4 million at December 31, 2025, from $601.9 million at December 31, 2024.
• Cash provided by operating activities decreased to $156.1 million in 2025 from $213.4 million in 2024.
• The company repurchased 2.9 million shares for $75.6 million in 2025 under its share buyback program.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative report. While new product launches and strong BAQSIMI growth are positive, the significant decline in net income, gross profit, and operating cash flow, coupled with increased G&A expenses from a legal settlement, indicates operational challenges and reduced profitability in the current period.

Positives

• BAQSIMI sales increased by 46% to $185.4 million in 2025, driven by the company assuming full global distribution responsibilities.
• Primatene MIST sales increased by 7% to $108.7 million in 2025, supported by continued marketing efforts.
• Successful launch of albuterol sulfate inhalation aerosol in August 2024 and iron sucrose injection in August 2025, contributing to 'Other products' revenue growth.
• FDA approval of teriparatide injection in December 2025 and Ipratropium Bromide HFA inhalation aerosol in February 2026, expanding the product portfolio.
• Vertical integration strategy, including in-house API manufacturing, provides better operating efficiencies, accelerated product development, and improved supply chain control.
• Robust pipeline with over 10 product candidates, including complex generics, biosimilars (e.g., interchangeable insulin analogs), and proprietary products.
• Maintained compliance with all debt covenants as of December 31, 2025 and 2024.
• Effective internal control over financial reporting as of December 31, 2025, as audited by Ernst & Young, LLP.

Negatives

• Total net revenues decreased by 2% from $732.0 million in 2024 to $719.9 million in 2025.
• Net income significantly decreased to $98.1 million in 2025 from $159.5 million in 2024.
• Gross profit decreased by 5% and gross margin declined from 51% to 49% in 2025, partly due to lower pricing for higher-margin products like glucagon and epinephrine.
• Epinephrine sales decreased by 25% due to lower unit volume and average selling price from increased competition.
• Glucagon sales decreased by 36% due to lower average selling prices and market shift to ready-to-use alternatives.
• General and administrative expenses increased substantially by 51% due to a $23.1 million legal settlement.
• Cash provided by operating activities decreased from $213.4 million in 2024 to $156.1 million in 2025.
• Significant customer concentration, with three major customers (McKesson, Cencora, Cardinal Health) accounting for 65% of total net revenues in 2025, posing credit risk and purchasing leverage concerns.

Risks

• Dependence on ability to develop and/or acquire and commercialize additional pharmaceutical products, with no guarantee of FDA approval or commercial success.
• Significant portion of net revenues derived from BAQSIMI, Primatene MIST, glucagon, epinephrine, and lidocaine; declines in sales volume or pricing of these products could materially affect financial results.
• Actual financial and operating results could differ materially from expectations or guidance.
• Reliance on single-source suppliers for raw materials and CMOs for BAQSIMI, with disruptions potentially negatively impacting business.
• Ability to develop new products and revenue streams depends on funding from ongoing revenue, borrowed funds, or additional capital, which may be affected by market volatility and economic instability.
• Significant competition in the pharmaceutical industry from both proprietary and generic drug companies, potentially limiting growth and affecting financial results.
• Healthcare providers may not be receptive to products, especially those with proprietary drug delivery platforms.
• Sales may be adversely affected by continuing consolidation of the customer base, leading to increased pricing pressures.
• Dependence on key personnel, the loss of whom could adversely affect operations and ability to attract and retain talent.
• Adverse effects from challenging macroeconomic conditions globally, including inflation and interest rate changes.
• Risks associated with manufacturing operations in China, including disruptions, political unrest, tariffs, and changes in trade policies.
• Exposure to product liability claims, with insurance coverage potentially inadequate for all expenses or losses.
• FDA approval process for product changes is time-consuming and complicated, potentially delaying or preventing manufacture or marketing.
• Clinical failure can occur at any stage of development, and early trial results are not predictive of future success.
• Novel use of particle engineering or synthetic APIs may not receive regulatory approval or market acceptance.
• Fast track designation may not lead to faster development or approval, and does not increase likelihood of marketing approval.
• Commercial success of NDA product candidates depends on the scope of FDA-approved indications and claims.
• Generic products may not be substitutable at the pharmacy level in all states, reducing sales.
• Investments in biosimilar products may not result in approved or commercially successful products due to regulatory uncertainties and competition.
• Products used with drug delivery or companion diagnostic devices have their own regulatory, manufacturing, and reimbursement risks.
• Failure to obtain regulatory approval in foreign jurisdictions would prevent marketing abroad.
• Branded pharmaceutical companies' efforts to limit generic use through legislative or regulatory means could harm generic product sales.
• Failure to obtain insurance coverage or adequate reimbursement from third-party payers could adversely affect revenues.
• Failure to comply with cGMP regulations may prevent or delay manufacture or marketing of products.
• Operations are subject to environmental, health and safety laws, with compliance being costly and exposing to penalties for non-compliance.
• The Affordable Care Act and other legislation/regulatory proposals may increase compliance costs and negatively impact profitability.
• Complexity of reporting and payment obligations under Medicare/Medicaid drug rebate programs, with potential for penalties for non-compliance.
• Enforcement action if engaging in off-label promotion of products.
• Exposure to fraud and abuse laws (Anti-Kickback Statute, False Claims Act, HIPAA, FCPA), with potential for significant fines and penalties.
• Risk of misconduct or improper activities by employees, independent contractors, consultants, commercial partners, and vendors.
• Adverse changes to import restrictions relating to animal-derived products could disrupt the supply chain.
• Enhanced trade tariffs, import/export restrictions, Chinese regulations, or other trade barriers may harm business.
• Exposure to governmental export control and trade sanctions laws.
• Chinese government influence over business operations in China and uncertainties in the Chinese legal system.
• Impact of increasing sanctions and export controls targeting Russia and other responses to Russia's invasion of Ukraine.
• Uncertainty in intellectual property protection, with patents potentially challenged, invalidated, or circumvented.
• Involvement in patent litigation or other intellectual property proceedings, resulting in damages or delays.
• Inadequate protection of unpatented trade secrets, know-how, confidential, and proprietary information.
• Delays in patent and trademark review and approval.
• Claims of using or disclosing alleged trade secrets or proprietary information belonging to third parties.
• Sales of substantial amounts of common stock, or indications of intent to sell, may cause stock price to decline.
• Concentration of ownership by key executives and directors, influencing stockholder approval matters.
• Pledging of common stock by key executives and directors could lead to forced sales and stock price decline.
• No intention to pay dividends for the foreseeable future.
• Future decisions to reduce or discontinue share repurchases could cause stock price to decline.
• Anti-takeover provisions in charter documents and Delaware law could discourage acquisitions.
• Global macroeconomic conditions may negatively affect the company and magnify certain risks.
• Adverse effects from labor shortages, turnover, and labor cost increases.
• Complications with the design or implementation of a new enterprise resource planning (ERP) system.
• Failure to maintain adequate internal controls or implement new/improved controls.
• Inherent uncertainties in estimates, judgments, and assumptions used in financial statements, potentially leading to restatements.
• Changes in financial accounting standards or practices could affect reported results.
• Changes in tax laws, tax rulings, and other factors may adversely impact effective tax rate and expense.
• Adverse effects from earthquakes or other natural disasters, with business continuity plans potentially inadequate.
• Quarterly and annual operating results may fluctuate significantly or fall below expectations, causing stock price volatility.
• Requirements of being a public company may strain resources and divert management attention.
• Potential involvement in securities class action litigation.

Future Outlook

The company anticipates continued decline in glucagon sales due to competitive dynamics and expects epinephrine and other product sales to fluctuate based on competitor supply. Research and development expenses are projected to increase annually due to rising clinical trial costs for insulin and inhalation product candidates. The company plans to increase manufacturing capacity at its Rancho Cucamonga, CA plant (to quadruple units), Canton, MA inhalation facility, and ANP insulin API production facility. Future cash flows are expected from new product launches, though regulatory approval and launch timing remain uncertain.

Management Comments

• We are currently developing a portfolio of generic abbreviated new drug applications, or ANDAs, biologics license applications, or BLAs, including biosimilar insulin product candidates and proprietary product candidates, which are in various stages of development and target a variety of indications.
• Our primary strategic focus is developing and commercializing products with high technical barriers to market entry.
• We believe our vertical integration allows us to achieve better operating efficiencies, accelerated product development, improved supply chain control, more flexibility in responding to market demands, and internal control over product quality.
• We aim to be an industry leader in developing, manufacturing, and commercializing technically challenging injectable, inhalation and intranasal pharmaceutical products.
• We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business.
• We expect that research and development expenses will increase on an annual basis due to increased clinical trials costs related to our insulin and inhalation product candidates.
• We believe that our cash reserves, operating cash flows, and borrowing availability under our credit facilities will be sufficient to fund our operations for at least the next 12 months from the filing of this Annual Report on Form 10-K.

Industry Context

StockSavvy.ai notes that Amphastar's strategic focus on technically challenging generic and proprietary products, particularly in injectables and inhalables, positions it in high-barrier-to-entry segments of the pharmaceutical market. The decline in sales of older generic products like glucagon and epinephrine due to increased competition is a common industry trend, underscoring the importance of a robust pipeline and continuous new product introductions. The significant investment in R&D and facility expansion reflects a broader industry push towards innovation and vertical integration to control costs and supply chains, especially in a volatile global economic and regulatory environment. The acquisition of BAQSIMI and licensing agreements for new compounds align with the industry's pursuit of higher-value, branded, and biosimilar opportunities to offset generic price erosion.

Comparison to Industry Standards

• Amphastar's 2025 net revenue of $719.9 million and net income of $98.1 million reflect a mixed performance compared to larger pharmaceutical players like Pfizer, Inc. or Viatris Inc., which operate on a much larger scale with multi-billion dollar revenues. However, within its niche of technically challenging generics and proprietary injectables/inhalables, its growth in BAQSIMI and Primatene MIST is notable.
• The 46% growth in BAQSIMI sales is strong, especially as the company took over full distribution, indicating successful integration and market penetration for this key product. This contrasts with the typical decline seen in mature generic products.
• The 36% decline in glucagon sales and 25% in epinephrine sales due to increased competition is a common challenge in the generic pharmaceutical market, where new entrants rapidly erode market share and pricing. Competitors like Viatris, Cipla, and Lupin also market or plan to market generic glucagon, intensifying this pressure.
• The company's R&D expenditure of $85.8 million in 2025, representing approximately 11.9% of net revenues, is a substantial commitment, comparable to the R&D intensity seen in innovative biopharmaceutical companies, reflecting its focus on complex and biosimilar candidates.
• The gross margin of 49% is respectable for a company with a significant generic portfolio, though the 2% decline from 2024 highlights pricing pressures and changes in product mix. Companies with a higher proportion of branded or specialty products typically command higher gross margins.
• The increase in general and administrative expenses due to a legal settlement is a specific event, but legal proceedings, particularly patent and product liability claims, are a pervasive risk across the pharmaceutical industry, affecting companies of all sizes.

Management Changes

Corporate Governance

Legal Proceedings

• A former employee initiated an employment litigation on April 15, 2024, against Amphastar and IMS, with individual and class action claims under California Labor Code, including PAGA, wage and hour violations. Individual and class claims were dismissed in November 2024, leaving only the PAGA claim.
• Another former employee initiated an employment litigation on June 20, 2024, against Amphastar, IMS, and Roth Staffing Companies L.P., with individual and class action claims under California Labor Code, including wage and hour violations.
• A third former employee initiated a class action litigation on October 30, 2025, against Amphastar and IMS, with claims under California's PAGA, wage and hour, and other state laws.
• A personal injury lawsuit resulted in a jury verdict on October 22, 2025, awarding the plaintiff $34.1 million. The company paid $23.1 million (after $11.0 million covered by insurance) in settlement in November 2025, which was recorded in general and administrative expenses.

Related Party Transactions

• The company has an 11.5% ownership in Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (Hanxin), which is accounted for as an equity method investment. Henry Zhang, son of Dr. Jack Zhang (CEO), is an equity holder, general manager, and chairman of Hanxin. Dr. Mary Luo (COO) and Dr. Jack Zhang also have ownership in Hanxin through an affiliated entity.
• Contract manufacturing agreements with Hanxin and its subsidiaries: Hanxin develops APIs and finished products for the Chinese market, and the company manufactures products on a cost-plus basis. Revenues from these services were $1.1 million in 2025.
• Contract research agreements with Hanxin: Hanxin develops Recombinant Human Insulin Research Cell Banks and Recombinant Peptide Research Cell Banks for the company. Payments under this agreement were $0.4 million in 2025.
• Supply agreement with Nanjing Letop Biotechnology Co., Ltd. (Letop): Letop, a related party due to Henry Zhang's ownership, manufactures chemical intermediates for the company on a cost-plus basis. Immaterial payments were made in 2025.
• Distribution agreement with Hong Kong Genreach Limited (Genreach), a wholly-owned subsidiary of Hanxin: Genreach is the exclusive distributor for Primatene MIST in Greater China, the Middle East, and Southeast Asia. No revenue was recognized in 2025 from this agreement.
• Distribution agreement with Nanjing Chengong Pharmaceutical Co., Limited (Chengong), a wholly-owned subsidiary of Hanxin: Chengong is the exclusive distributor for BAQSIMI in the Greater China Region. No revenue was recognized in 2025 from this agreement.

Stakeholder Impact

• Shareholders: Experienced a decline in net income and gross profit, potentially impacting stock performance. Share repurchases may offer some support, but increased debt and legal expenses are concerns. The concentration of ownership by key executives could influence corporate decisions.
• Employees: The company continues to invest in R&D and expand facilities, suggesting job stability and growth opportunities. Competitive compensation and benefits packages are offered. However, labor shortages and increased turnover are noted risks.
• Customers (Wholesalers/Distributors/Pharmacies): Consolidation in the customer base leads to increased purchasing leverage and pricing pressures. Supply chain integrity and product availability are critical for customer relationships.
• Patients: New product approvals (iron sucrose, teriparatide, Ipratropium Bromide HFA) expand treatment options. However, product liability risks and potential for off-label promotion enforcement could impact patient safety and access.
• Suppliers: Dependence on single-source suppliers and CMOs creates risk for the supply chain. Compliance with FDA regulations is crucial for continued operations.
• Creditors: Increased indebtedness from the BAQSIMI acquisition and convertible notes means higher principal and interest payment obligations. Restrictive covenants in loan agreements limit operational flexibility.

Next Steps

• Launch Ipratropium Bromide HFA inhalation aerosol early in the second quarter of 2026.
• Continue substantial investments in research and development, particularly for insulin and inhalation product candidates.
• Increase manufacturing capacity at the Rancho Cucamonga, CA plant, Canton, MA inhalation facility, and ANP insulin API production facility.
• Pursue regulatory approvals for one ANDA and one biosimilar insulin candidate currently on file with the FDA.
• Develop and commercialize three identified Licensed Products under the agreement with Nanjing Anji Biotechnology Co., Ltd.
• Develop, make, use, and commercialize corticotropin compound in the United States and Canada under the license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
• Expand distribution of Primatene MIST to the Middle East and Southeast Asia regions through Hong Kong Genreach Limited.
• Collaborate with Nanjing Chengong Pharmaceutical Co., Limited to expand distribution of BAQSIMI in the Greater China Region, including obtaining regulatory approvals and performing post-marketing clinical trials.
• Monitor and evaluate the impact of new accounting standards (ASU 2024-03, ASU 2024-04, ASU 2025-06) on consolidated financial statements and disclosures.
• Continue to defend against ongoing employee litigation matters.

Key Dates

Recommendation

Amphastar Pharmaceuticals presents a mixed financial picture for 2025. While strategic product launches (iron sucrose, teriparatide) and strong growth in BAQSIMI and Primatene MIST are positive indicators of future revenue diversification, the significant decline in overall net income and gross profit, coupled with increased operating expenses due to a substantial legal settlement, raises concerns about near-term profitability. The company's robust R&D pipeline and vertical integration are long-term strengths, but intense generic competition for existing products like glucagon and epinephrine continues to exert pressure. Given the current financial headwinds and ongoing investments, a 'hold' recommendation is appropriate, allowing investors to monitor the successful integration and commercialization of new products and the resolution of cost pressures before making further investment decisions.

Keywords

Biopharmaceutical, Injectable drugs, Inhalation products, Intranasal products, Generic drugs, Proprietary drugs, Biosimilars, BAQSIMI, Primatene MIST, Glucagon, Epinephrine, Lidocaine, Iron sucrose, Teriparatide, Ipratropium Bromide HFA, API manufacturing, FDA approval, Clinical trials, Pharmaceutical R&D, Supply chain, Intellectual property, Healthcare regulation, SEC filing, 10-K